Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0677930 (primary tumor)
 20,210 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Our early experience using microSelectron HDR to treat cervical cancer patients at Osaka University Hospital is presented. From June 1991 through December 1992, a total of 20 patients (stage Ib, 6; stage IIa, 2; stage IIb, 5; stage IIIb, 6 and stage IVa, 1) with previously untreated invasive uterine cervical cancer and intact uterus were treated with high-dose rate intracavitary therapy administered with a microSelectron. For the treatment, a standard rigid applicator made of stainless steel for a microSelectron was used. Twenty to 30 Gy of external irradiation was administered to the whole pelvic field and 30 to 20 Gy to the central shielded field (total 50 Gy/5-6 weeks) for patients in stage II-IVa. For stage Ib, 40 Gy was delivered to the central shielded field. The 192Ir source had an activity of 370 GBq as of the measuring time. Source loading corresponded to the Manchester System for cervical cancer. Thirty-two or 30 Gy was administered at point A in four fractions over four weeks of intracavitary irradiation. Early primary tumor responses for all patients were complete. There have been two local recurrences in stage IIb and IIIb patients. Three patients in stages Ib, IIb, and IIIb developed para-aortic lymph node metastases, and two of them died from generalized metastasis. No acute radiation injury has been observed. One patient in stage IIb developed subileus five months after irradiation. From our early experience, it is concluded that microSelectron HDR can be used for cervical cancer patients as safely and effectively as our previously used high-dose rate machine.
 ...
PMID:High-dose rate intracavitary therapy for cervical cancer with a microSelectron: a preliminary report. 815 67

Intraoperative radiotherapy (IORT) is a new concept in the treatment of recurrent and primary advanced colorectal tumors. Between October 1994 and December 1997 27 patients (primary tumor: 8, first recurrent tumor: 12, second recurrent tumor: 7) received IORT (32 applications). Chemotherapy and percutaneous radiotherapy had already been given to all patients with advanced and recurrent colorectal tumors. The intraoperative irradiation was performed through HDR iridium afterloading. A flexible flab--individually adapted to the "tumor bed"--was used as applicator. The contact dose ranged from 10 to 15 Gy. The mean operation time (rectum resection: 5, rectum amputation: 14, debulking: 8) increased by 30 min on average. Eight patients had postoperative complications: perianal wound infections (3), sacrovesical fistulas (3), leakage of anastomosis (1) and neural ureter dysfunction (1). To date--on average 17.1 months (range: 3-33) after operation--13 patients are free of tumor recurrence or show stable disease. Ten patients--all of them had macroscopic residual tumor--have local tumor progression combined with good quality of life. Only 4 patients died (acute kidney failure, stroke, marasmus, systemic progression). The afterloading flab technique represents a technically simple, minimally harmful procedure in the therapy of colorectal tumor. Even when IORT with electrons is not feasible or the patients have already been irradiated, a higher radiation dose is possible. Given the demonstrated rate of local tumor recurrence, the afterloading flab technique seems to be a valuable treatment alternative to extended, high-risk resections. Long-term follow-ups will be necessary.
 ...
PMID:[In Process Citation] 1006 22